NCT06478186View on ClinicalTrials.gov

Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

July 16, 2026

Study Completion Date

October 16, 2026

Conditions
Osteoarthritis, KneeDiabetes Mellitus, Type 2
Interventions
DRUG

triamcinolone acetonide extended-release injectable suspension; TCA-ER

Mode of Administration: IA Knee Injection Nominal 32 mg TCA, intra-articular (IA) injection, administered as a 5 mL injection

DRUG

Triamcinolone Acetonide- Immediate Release;TCA-IR

Mode of Administration: IA Knee Injection Triamcinolone Acetonide- Immediate Release (TCA-IR)

Trial Locations (1)

66160

RECRUITING

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER